NCT05482074View on ClinicalTrials.gov

Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

October 4, 2022

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2027

Conditions

Recurrent Metastatic MelanomaCutaneous MelanomaMucosal MelanomaUveal Melanoma

Interventions

DRUG

Olaparib

Oral, twice a day, dosage per protocol, per 28 day cycle

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER